Scholar Rock Shares Quadruple On Positive Drug-Study Results

Oct 7, 2024 · Shares of Scholar Rock rose to $31.36 in mid-day trading, up from $7.42 on Friday, though shares are still off more than 50% from their intraday peak of $68.02 in March 2021, …

CouponFollow Extension

50%
OFF

Scholar Rock Shares Quadruple On Positive Drug-Study Results

3 weeks from now

Oct 7, 2024 · Shares of Scholar Rock rose to $31.36 in mid-day trading, up from $7.42 on Friday, though shares are still off more than 50% from their intraday peak of $68.02 in March 2021, …

wsj.com

$1
OFF

Scholar Rock Shares Quadruple On Positive Drug-Study Results

3 weeks from now

Oct 14, 2024 · Shares of biotech company Scholar Rock saw a dramatic increase on Monday, with the stock price more than quadrupling. This surge added approximately $1.9 billion to the …

financialeducationblog.com

320%
OFF

Scholar Rock Shares Soar 320% On Positive SMA Trial Results

3 weeks from now

Jan 24, 2025 · The rapid rise in Scholar Rock’s share price reflects not just the immediate excitement surrounding apitegromab, but also a broader narrative about innovation in biotech. …

thefinancialanalyst.net

335%
OFF

Scholar Rock (SRRK) Shares Surge On Successful SMA Drug Trial

3 weeks from now

Oct 8, 2024 · Shares of Scholar Rock Holding Corp. (SRRK, Financial) soared by 335% as their candidate drug for spinal muscular atrophy (SMA), apitegromab, achieved the primary …

gurufocus.com

362%
OFF

SRRK Stock Soars As Muscle Disease Drug Meets Phase III Study Goal

3 weeks from now

Oct 8, 2024 · Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and …

nasdaq.com

364%
OFF

Here's Why Everybody's Talking About Scholar Rock Right Now

3 weeks from now

Oct 9, 2024 · Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage …

yahoo.com

$300
OFF

Scholar Rock Scores $300M For Regulatory Filings & Launch Plans …

3 weeks from now

Oct 9, 2024 · After positive data from a pivotal study sent the biotech’s shares skyward, Scholar Rock has raised $300 million from a stock offering that will be applied toward regulatory …

medcitynews.com

07%
OFF

SRRK - Scholar Rock Holding Corp Stock Price And Quote

3 weeks from now

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%. 06:13AM ... Scholar Rock Shares Quadruple On Positive Drug-Study …

finviz.com

85%
OFF

Here's Why Everybody's Talking About Scholar Rock Right Now

3 weeks from now

Oct 9, 2024 · Shares of Scholar Rock (SRRK-2.85%) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's …

fool.com

362%
OFF

SRRK Stock Soars As Muscle Disease Drug Meets Phase III Study Goal

3 weeks from now

Oct 8, 2024 · Shares of Scholar Rock (SRRK Quick Quote SRRK - Free Report) skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage …

zacks.com

$31.91
OFF

Scholar Rock Surges As Genetic Disease Drug Succeeds In Late-stage ...

3 weeks from now

Oct 7, 2024 · ** Shares of Scholar Rock SRRK more than quadruple in value to $31.91 ** Stock set to hit nearly 3-year high if gains hold ** Says its drug, apitegromab, met the main goal in a …

tradingview.com

FAQs about Scholar Rock Shares Quadruple On Positive Drug-Study Results Coupon?

Is scholar rock a candidate for a larger biopharma company?

In his Monday note, Yee wrote that the new data makes Scholar Rock an attractive candidate for acquisition by a larger biopharma company active in spinal muscular atrophy, or related areas. Scholar Rock shares had traded as high as $68 in March 2021, but the stock has plummeted since, along with many other the smaller and midsize biotech players. ...

How does the scholar rock drug work?

While a number of drugmakers, including Biogen and Roche Holding, sell treatments for the condition, the approved drugs target the genetic defect in patients and mostly work to slow the progression of the condition. The Scholar Rock drug works differently, targeting a protein that inhibits muscle growth. ...

How did scholar rock perform in Q2 2024?

Scholar Rock has reported its second-quarter results for 2024. The company did not generate any revenue for the quarter. However, compared to the same period last year, there was a noticeable increase in the net loss, from $37.9 million in Q2 2023 to $58.5 million. ...

Is scholar rock a good stock to buy for the Embraze trial?

At recent prices, Scholar Rock boasts a $2.5 billion market cap. This is an appropriate valuation for a company likely to earn approval for an SMA treatment late next year. That said, this stock's present valuation isn't pricing in any success for the Embraze trial. Scholar Rock is a high-risk stock best avoided by most individual investors. ...

Will scholar rock get US approval?

The company plans to seek U.S. and European Union approval for the medicine in the first quarter of next year. Shares of Scholar Rock rose to $31.36 in mid-day trading, up from $7.42 on Friday, though shares are still off more than 50% from their intraday peak of $68.02 in March 2021, according to FactSet. ...

Why did scholar rock raise $300 million?

After positive data from a pivotal study sent the biotech’s shares skyward, Scholar Rock has raised $300 million from a stock offering that will be applied toward regulatory submissions and launch preparation of what could become its first commercialized product. ...